What We Do
Medical Need
Improved Time-to-Market
Initial Disease Focus
We are developing new, more potent antibody therapeutics by transforming existing clinically proven antibody therapeutics for an improved patient response.
Initial Disease Focus
Improved Time-to-Market
Initial Disease Focus
Our team is prioritizing cancer therapies such as non-Hodgkin lymphoma (NHL),
Chronic Lymphocytic Leukemia (CLL), and HER2-positive breast cancer.
Improved Time-to-Market
Improved Time-to-Market
Improved Time-to-Market
We are a therapeutic start-up based on a platform technology, radically de-risking drug discovery and development.